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Abstract
Background: Biliary cancer includes cancer of the gallbladder as well as extrahepatic and
intrahepatic cholangiocarcinoma. Surgery is the only curative treatment option available. Recently,
much more aggressive surgical approaches have been employed. Therefore, we have investigated
outcome of biliary cancer before and after establishment of an aggressive surgical approach.
Methods: Retrospective single-center analysis comparing two time periods of 5 years each. During
the second period new surgical expertise and a much more aggressive surgical approach were used.
Results: In the first time period (5/1995–4/2000) only 29 patients with biliary cancer were treated
at our institution, while a total of 85 patients were treated during the second time period (5/2000–
4/2005). Surgical resection was attempted in 55% during the first period versus 62% in the second;
resection was complete in 37.5% and 58.5%, respectively. Patients undergoing resection during the
second time period were more likely to be without relapse compared with patients undergoing
resection in the first time period. No patient from the first period is without evidence of disease,
compared to 11 patients operated in the second period. Resected patients had better survival
compared with unresected patients for all tumor locations (gallbladder, extrahepatic and
intrahepatic cholangiocarcinomas). Overall survival of patients was not significantly different
between patients treated during the first versus the second time period.
Conclusion: In patients with biliary cancer surgical resection should be attempted whenever
possible. However, long-term survival can be achieved only when a complete resection is obtained.
Background
Biliary cancer is a rare disease with a bad prognosis. This
disease encompasses gallbladder cancer, extrahepatic
cholangiocarcinoma of the perihilar region and of the dis-
tal choledochus as well as intrahepatic cholangiocarci-
noma. (The latter location was traditionally grouped with
liver tumours). In recent years more active surgical and
chemotherapeutic approaches in the treatment of biliary
cancer have been employed. The impact of these
approaches is difficult to assess although based on surgi-
cal series[1,2] and a single randomized trial of chemother-
apy versus best supportive care[3] these treatments have
become general practice. In this retrospective single center
series we analyse the impact on outcome of the increasing
use of an aggressive surgical approach.
Methods
We have performed a retrospective analysis of patients
with biliary cancer treated at the University Hospital in
Zurich over a 10 year period. Patients who had part of
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Patients were seen in the departments of visceral surgery
(43), oncology (41), both of these (19), or gastroenterol-
ogy (11). In all cases with missing follow-up information,
a letter with paid feed-back envelope was mailed to physi-
cians and/or other hospitals where patients were treated
to obtain a maximum of information.
In May 2000 a new head of visceral surgery was elected
with particular interest and expertise in biliary and liver
surgery. Since that time a much more active surgical
approach is used in the treatment of biliary cancer at our
institution. We were interested to analyse the impact of
this change in approach on patient outcome. Therefore,
we divided the patient population into two time periods
of equal duration based on the date of diagnosis. The first
time period includes patients with a diagnosis of biliary
cancer made between May 1, 1995 and April 30, 2000.
The second time period includes patients with a diagnosis
made between May 1, 2000 and April 30, 2005. Patient
and tumor characteristics, diagnostic and therapeutic pro-
cedures including type of surgery or biopsy, pathology,
imaging (including positron-emission tomography since
2001 to exclude metastatic disease),[4] laboratory find-
ings, chemotherapy, radiotherapy, and outcome were tab-
ulated and analysed by descriptive statistics. P-values were
calculated with log-rank test.
Results
Patient and tumor characteristics
Patient characteristics and tumor types are listed in Table
1. In the first five-year period (May 1, 1995 until April 30,
2000) only 29 patients with a diagnosis of biliary cancer
were treated at our institution. By contrast, in the second
five-year period (May 1, 2000 until April 30, 2005) 85
patients were seen. Median age was similar, 60 (range 32–
84) and 63 (34–80), respectively. There were 55.2%
females in the first period, and 51.8% in the second
period. Remarkably, in the first time period the propor-
tion of gallbladder cancer was much higher (44.8%) than
in the recent period (25.9%). Similarly, the proportion of
ductal cholangiocarcinomas was much lower in the first
time period, especially the intrahepatic cholangiocarcino-
mas: 13.8% in the first time period versus 27.1% in the
recent past. The proportion of extrahepatic cholangiocar-
cinomas was 37.9% and 45.9%, respectively.
Diagnostic procedures, type of surgery, and surgical
pathology are listed in Table 2. Diagnosis was most often
made by tumor biopsy or tumor resection, and only rarely
by cytology. Type of surgery has significantly changed in
the second time period with 44.7% liver resections with
curative intent compared to only 17.2% in the first time
period. Conversely, smaller resections like resection of
extrahepatic bile ducts alone (10.3% versus 4.7%) or
cholecystectomy only (17.2 % versus 4.7%) as well as sur-
gery without resection (17.2% versus 14.1%) were more
frequently performed in the first time period. Not surpris-
ingly, histology was adenocarcinoma in a very large
majority, with a few cases of papillary adenocarcinoma
and squamous cell carcinoma in the second time period.
Tumor grading was similar in the two time periods; grad-
ing in the first/the second time period: G1 10.3%/5.9%,
G2 34.5%/52.9%, G3 31.0%/16.5%, unknown 24.1%/
24.7%.
TNM-staging of all patients is shown in Table 3. It is evi-
dent that a correct T-stage could not be assigned based on
imaging alone, but only when a resection was performed.
Conversely, in about one third of patients, assignment of
the N-stage was based on imaging studies. CT-scanning
was performed in most patients: 84.0% in the first time
period, and 87.2% in the second. Use of ultrasound has
decreased, from 80% in the first time period to 57.7% in
the second. On the contrary, the use of MRI has increased
from 16.0% to 34.6%, respectively. Use of the tumor
marker CA 19-9 has also increased from 27.6% to 63.5%.
The preoperative values measured are very similar:
Median (range) CA 19-9 was 72.8 kU/l (4.9–1340) in the
first time period, compared with 74.8 kU/l (0-72'900) in
the second time period.
Treatment
The only curative treatment of cholangiocarcinoma is sur-
gical resection. In the first time period, 12 of 29 patients
underwent resection with curative intent (41.4%), com-
pared to 51 of 85 (60.0%) in the second time period. Fol-
low-up of surgically resected patients is shown in Figure 1.
Time to relapse is longer for patients treated in the second
time period (p = 0.064). In the first time period only 6 of
16 (37.5%) resections were complete resections, com-
pared to 31 of 53 (58.5%) resections in the second time
period. All 6 patients of the first time period having
undergone complete resection have relapsed. So far, 20 of
the 31 later patients having undergone complete resection
have relapsed, while 11 patients are without evidence of
Table 1: Patient characteristics and tumor type
Characteristic 1995–2000 2000–2005
N % N %
Number of patients 29 100 85 100
Median age (range)    60        (32–84)   63        (34–80)
Gender female/male 16/13 55.2/44.8 44/41 51.8/48.2
Gallbladder carcinoma 13 44.8 22 25.9
Intrahepatic CCC 4 13.8 23 27.1
Extrahepatic CCC 11 37.9 39 45.9
Tumor localization unknown 1 3.4 1 1.2
CCC = cholangiocarcinomaPage 2 of 9
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case has been successfully treated with combined modal-
ity therapy involving neoadjuvant chemo-radiation fol-
lowed by living donor liver transplantation from a sibling
who had previously donated bone marrow to the patient
for acute lymphoblastic leukaemia.[5,6]
Chemotherapy was used in about half the patients: 44.8%
in the first time period, and 55.3% in the second period.
Two patients received adjuvant chemotherapy, while in all
other patients chemotherapy was given with palliative
intent. In early times fluorouracil (23.8%), gemcitabine
(28.6%) or the ECF (epirubicin-cisplatin-fluorouracil)
combination (28.6%) were applied while in the second
period gemcitabine monotherapy was the dominant
choice (58%), followed by ECF (16.1%). There was no
significant survival difference in the 13 patients treated
with chemotherapy during the first time period compared
to the 47 patients treated with chemotherapy during the
second time period. In addition, overall survival was sim-
ilar from diagnosis between all patients undergoing
chemotherapy at some point in time compared to all
patients never receiving chemotherapy.
Radiation treatment was given with neoadjuvant intent to
1 exceptional patient (see above), to 2 patients with adju-
vant intent, and to 10 patients with palliative intent (1 to
primary tumor, 9 to metastases).
Survival
Overall survival is shown in Figure 2. Patients treated in
the first time period had a similar survival from diagnosis
as patients in the second time period. Similarly, when
analysing survival according to primary tumor location
(see Table 1), no significant differences in overall survival
were found. Comparison was made in 13 versus 22 carci-
nomas of the gallbladder, 4 versus 23 intrahepatic cholan-
giocarcinomas, and 11 versus 39 extrahepatic
cholangiocarcinomas (figures not shown).
Table 2: Diagnostic procedures, type of surgery, surgical 
pathology
Time period 1995–2000 2000–2005
N % N %
Number of patients 29 100 85 100
DIAGNOSTIC PROCEDURE
Resection specimen 10 34.5 42 50.0
Tumor biopsy 17 58.6 38 45.2
Brush cytology 2 6.9 3 3.6
Diagnosis established by follow-up 0 - 1 1.2
SURGERY
Resection 16 55.2 53 62.4
Liver resection 5 17.2 38 44.7
Whipple operation 2 6.9 6 7.1
Transplantation 1 3.4 1 1.2
Resection of extrahepatic bile ducts only 3 10.3 4 4.7
Cholecystectomy only 5 17.2 4 4.7
Non-resection surgery 5 17.2 12 14.1
Excision of lymph nodes only 0 - 1 1.2
Exploratory laparoscopy 1 3.4 6 7.1
Exploratory laparotomy 2 6.9 4 4.7
Surgical biopsy 2 6.9 1 1.2
No surgery 8 27.6 20 23.5
SURGICAL PATHOLOGY
Adenocarcinoma NOS 26 89.7 75 88.2
Papillary adenocarcinoma 0 - 3 3.5
Squamous cell carcinoma 0 - 3 3.5
Unknown 3 10.3 4 4.7
NOS = not otherwise specified
Table 3: Staging
Time period 1995–2000 2000–2005
Resection Yes No Yes No
Number of patients 16 13 53 32
T-Stage
T1 0 0 11 0
T2 5 0 11 0
T3 5 0 27 0
T4 3 0 3 0
Unknown 3 13 1 32
N-Stage
N0 4 2 31 3
N1 6 2 17 8
Unknown 6 9 5 21
M-Stage
M0 6 1 46 13
M1 2 7 4 12
Unknown 8 5 3 7Page 3 of 9
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than in non-resected patients (p = 0.000) as shown in Fig-
ure 3. This was true and very alike for both time periods
(data not shown). Taking a close look at Figure 3 shows
that no un-resected patient has survived 3 years, while
more than 30% of resected patients are alive at the 3-year
time interval.
Resected patients had superior survival to non-resected
patients in all 3 tumor locations: Carcinoma of the gall-
bladder (Figure 4), intrahepatic cholangiocarcinoma (Fig-
ure 5), as well as extrahepatic cholangiocarcinoma (Figure
6).
Survival in carcinoma of the gallbladder was significantly
worse than survival in ductal cholangiocarcinoma (p =
0.001) as shown in Figure 7. This was also true when
either intrahepatic or extrahepatic cholangiocarcinoma
was compared separately with gallbladder carcinoma. Sur-
vival of intrahepatic versus extrahepatic cholangiocarci-
noma was not significantly different with a minimal
advantage for extrahepatic disease (data not shown).
Table 4 shows outcome, and how it relates to initial stage.
It is apparent that the only patients free of disease are
those who have a T1, T2, or rarely T3 disease. There was
not a single patient with lymph node involvement who
has not relapsed.
Discussion
In this retrospective study we have compared patients
with biliary cancer treated at our institution in two time
periods. With the advent of new expertise in the depart-
ment of visceral surgery the patient volume with biliary
cancer treated at our institution has almost trippled in the
second period, increasing from less than 6 patients per
year to 17 patients per year. This is certainly due to a
change in referral, and not due to an increase in the inci-
dence of the disease nor to changes in diagnostic evalua-
tion. It is very likely that many patients with biliary cancer
Proportion without relapse after resectionFigure 1
Proportion without relapse after resection. The proportion of patients without relapse over time is shown for the two 
time periods. In the first period only 6 of 16 resected patients had complete resections (37.5%), 10 have relapsed immediately. 
In the second time period 31 of 53 patients had complete resections (58.5%), 22 had relapsed immediately. Similarly during fur-
ther follow-up, time to relapse after resection remained increased for the second time period (p = 0.064).Page 4 of 9
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simply not referred, probably for various reasons includ-
ing the perception that therapeutic options were limited.
It is likely that this has lead to "backward stage migra-
tion": While only the "best" patients were operated during
the first period, patients with more advanced disease were
referred during the second time period. In the first period,
almost half the patients had gallbladder tumors; some of
them had incidental gallbladder adenocarcinoma diag-
nosed histologically after cholecystectomy. In the second
Resection and survivalFigure 3
Resection and survival. Survival of patients undergoing resection was significantly increased compared with patients not 
undergoing resection (p = 0.000). This is shown for all patients. It was also true for patients of the first time period (N = 29), 
and for patients of the second time period (N = 85).
Overall survivalFigure 2
Overall survival. Overall survival of patients treated in the first time period is comparable to the second time period. Survival 
of gallbladder carcinoma as well as of cholangiocarcinoma (intrahepatic and extrahepatic) was also similar during the first and 
the second time period (not shown).Page 5 of 9
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Resection for gallbladder cancer and survivalFigure 4
Resection for gallbladder cancer and survival. Survival of patients having undergone resection for gallbladder cancer was 
superior to survival of non-resected patients (N = 35).
Resection for intrahepatic cholangiocarcinoma and survivalFigure 5
Resection for intrahepatic cholangiocarcinoma and survival. Survival of patients having undergone resection for intra-
hepatic cholangiocarcinoma was superior to survival of non-resected patients (N = 27).
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Resection for extrahepatic cholangiocarcinoma and survivalFigure 6
Resection for extrahepatic cholangiocarcinoma and survival. Survival of patients having undergone resection for ext-
rahepatic cholangiocarcinoma was superior to survival of non-resected patients (N = 50).
Survival and tumor locationFigure 7
Survival and tumor location. Survival was related to tumor location. Gallbladder carcinoma had significantly worse progno-
sis than cholangiocarcinoma (p = 0.001). There was no significant difference between intrahepatic cholangiocarcinoma (ICC) 
and extrahepatic cholangiocarcinoma (ECC) while both had significantly better survival than gallbladder carcinoma. Median sur-
vival of gallbladder cancer was about 8 months, for ICC 20 months, for ECC 22 months.
International Seminars in Surgical Oncology 2007, 4:26 http://www.issoonline.com/content/4/1/26period the proportion of intrahepatic and extrahepatic
cholangiocarcinomas necessitating more extensive and
more demanding surgery was much higher.
Despite this referral bias the proportion of patients under-
going resection was slightly higher during the second time
period (62%, Table 2) than the first time period (55%).
Patients undergoing resection had a significantly better
outcome than non-resected patients (p = 0.000) (Figure
3). The advantage of undergoing resection was more
marked for extrahepatic cholangiocarcinoma than for int-
rahepatic cholangiocarcinoma and gallbladder cancer
(Figure 4, 5, 6). In addition, during the second time
period resection was more often complete and remission
(time without relapse) was prolonged (Figure 1). The only
patients without evidence of disease at this time are
patients having undergone resection for a low T-stage (T1,
T2 and very rarely T3) and N-stage (N0 only) (Table 4). In
the literature, the prognostic importance of N-stage and
the worth of extensive lymph node dissections is contro-
versial.[1,7,8] Most authors favour an aggressive and
extensive surgical approach. Unfortunately, in this analy-
sis probably skewed by referral bias, we were unable to
document increased overall survival for patients treated
during the second time period (Figure 2). There are many
explanations possible for this lack of better survival. The
populations of the two time periods are dissimilar in
many respects besides surgery, including type and propor-
tion of patients referred, location of the primary tumor,
stage distribution, diagnostic evaluations, palliative treat-
ments.
In the second time period the use of chemotherapy has
increased somewhat, from 45% to 55%. Chemotherapy
during the first time period was mostly fluorouracil-based
(57%) while during the second time period gemcitabine-
based chemotherapy (64%) was used most frequently. We
were unable to find a difference in overall survival
between patients treated with chemotherapy during the
second time period when compared with the first time
period. Looking at the variety of regimes and the differ-
ences in the patient populations as well as their restricted
numbers (13 patients in the first time period, 47 in the
second) no conclusions about palliative chemotherapy in
biliary cancer can be drawn. Similarly, in the literature the
worth of chemotherapy is controversial.[9] Nevertheless,
gemcitabine with or without capecitabine is considered a
reasonable choice for palliative treatment of advanced bil-
iary cancer.[10]
In conclusion, for the treatment of biliary cancer it is rea-
sonable to attempt complete resection, while incomplete
resections are probably of no avail.[7,11-13] We will fol-
low the 11 patients without evidence of disease from the
second time period in order to define how many (if any)
of them have been cured. No patient from the first time
period is without relapse. In order to define the worth of
chemotherapy in adjvanced biliary cancer a randomized
multicenter study comparing gemcitabine with the com-
bination of gemcitabine/capecitabine is planned.[10]
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